Epidemiologic and Genetic Study on Familial Prostate Cancer

C

Centre de Recherche sur les Pathologies Prostatiques

Status

Unknown

Conditions

Prostate Cancer

Study type

Observational

Funder types

Other

Identifiers

NCT01221168
ProGene

Details and patient eligibility

About

The aims of the study are: to identify genetic and molecular factors (rare mutations, polymorphisms) involved in the natural history of prostate cancers and their response to treatment, to evaluate and deduce their medical applications for screening and therapeutic management of these tumors.

Full description

The impact of genetic factors on the natural history of prostate cancer (PC) is shown schematically at two levels: first, at the constitutional level with germline alterations. Family history is found in 20% of PC patients. Different clinical entities associated with different modes of inheritance, susceptibility mutations or polymorphisms, define different evolutionary patterns. Also, studies suggested that some genetic polymorphisms alter the response to some treatments (such as recurrence after prostatectomy or radiotherapy) or adverse effects of those above (such as toxicity of radiation therapy). secondly, PC is characterized by the accumulation of genetic alterations (somatic alterations or acquired mutations). These changes contribute in varying degrees to the aggressiveness of the disease (such as early metastatic potential) and treatment failure (such as resistance to radiation or hormone resistance). The purpose of this study is to establish a register, with a follow up of cohort type and a collection of biological samples: For men with known prostate cancer. For men with no prostate cancer after a screening procedure for this disease, so that their biological samples can be compared to those of men with prostate cancer. The registry data and collected biological samples are used to identify genetic and molecular factors involved in susceptibility, genesis and evolution of prostate cancers.

Enrollment

6,000 estimated patients

Sex

All

Ages

18+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • patient with a histological confirmed prostate cancer
  • member of a hereditary prostate cancer family
  • healthy control men without prostate cancer

Exclusion criteria

  • Absence of signed informed consent
  • refusal to participate in the study

Trial design

6,000 participants in 1 patient group

Men with or without Prostate Cancer
Description:
Men with a histological confirmed prostate cancer, and their family members in case of hereditary prostate cancer. Men with no prostate cancer after a screening procedure for this disease, so that their biological samples can be compared to those of men with prostate cancer.

Trial contacts and locations

0

Loading...

Central trial contact

Olivier Cussenot, MD, PhD; Geraldine Cancel-Tassin, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems